[ANIK] Anika Therapeutics Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 49.53 Change: 0.9 (1.85%)
Ext. hours: Change: 0 (0%)

chart ANIK

Refresh chart

Strongest Trends Summary For ANIK

ANIK is in the long-term up 419% in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company?s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company?s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regen

Fundamental Ratios
Shares Outstanding EPS2.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40.93% Sales Growth - Q/Q-33.26% P/E21.89
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA13.56% ROE14.74% ROI
Current Ratio23.7 Quick Ratio21.67 Long Term Debt/Equity Debt Ratio0.03
Gross Margin76.03% Operating Margin49.46% Net Profit Margin30.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.9 M Cash From Investing Activities-6.01 M Cash From Operating Activities3.98 M Gross Profit17.63 M
Net Profit7.82 M Operating Profit12.43 M Total Assets208.01 M Total Current Assets155.73 M
Total Current Liabilities7.96 M Total Debt Total Liabilities17.44 M Total Revenue22.9 M
Technical Data
High 52 week68.43 Low 52 week30.16 Last close33.37 Last change-1.68%
RSI28.12 Average true range1.5 Beta0.55 Volume53.19 K
Simple moving average 20 days-12.46% Simple moving average 50 days-5.2% Simple moving average 200 days-30.71%
Performance Data
Performance Week-15.56% Performance Month-8.45% Performance Quart-24.07% Performance Half-50.76%
Performance Year-35.45% Performance Year-to-date-0.71% Volatility daily3.96% Volatility weekly8.86%
Volatility monthly18.15% Volatility yearly62.89% Relative Volume229.99% Average Volume131.63 K
New High New Low


2020-05-12 16:05:00 | Anika to Participate in 2020 UBS Virtual Global Healthcare Conference

2020-05-08 23:00:16 | Anika Therapeutics Inc ANIK Q1 2020 Earnings Call Transcript

2020-05-08 12:00:04 | Anika ANIK Moves to Buy: Rationale Behind the Upgrade

2020-05-07 16:05:10 | Anika Reports First Quarter 2020 Financial Results

2020-05-01 06:34:16 | Does Anika Therapeutics, Inc. NASDAQ:ANIK Have A High Beta?

2020-04-30 12:34:04 | Anika Therapeutics ANIK Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2020-04-28 11:40:03 | ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

2020-04-27 08:30:00 | Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer

2020-04-23 16:05:00 | Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7

2020-04-08 16:05:10 | Anika Takes Actions to Strengthen Liquidity in Light of COVID-19

2020-04-02 12:45:51 | 3 Benjamin Graham-Style Stocks

2020-03-26 06:12:48 | How Does Anika Therapeutics's NASDAQ:ANIK P/E Compare To Its Industry, After The Share Price Drop?

2020-03-11 07:51:34 | Can You Imagine How Anika Therapeutics's NASDAQ:ANIK Shareholders Feel About The 29% Share Price Increase?

2020-03-04 08:30:00 | Anika Appoints David Colleran as General Counsel

2020-02-27 07:52:12 | New Strong Sell Stocks for February 27th

2020-02-21 07:46:22 | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

2020-02-20 19:15:12 | Anika Therapeutics ANIK Beats Q4 Earnings and Revenue Estimates

2020-02-20 16:05:10 | Anika Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-13 12:31:05 | Analysts Estimate Anika Therapeutics ANIK to Report a Decline in Earnings: What to Look Out for

2020-02-12 16:05:10 | Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

2020-02-06 17:14:00 | CORRECTING and REPLACING Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20

2020-02-04 05:38:48 | Do You Like Anika Therapeutics, Inc. NASDAQ:ANIK At This P/E Ratio?

2020-02-03 16:30:10 | Anika Therapeutics Closes Acquisition of Arthrosurface

2020-01-29 16:30:10 | Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer

2020-01-24 16:05:10 | Anika Therapeutics Closes Acquisition of Parcus Medical

2020-01-13 15:00:00 | Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group

2020-01-08 11:47:25 | Massachusetts firm to acquire Sarasota sports medicine company for $35M

2020-01-06 08:30:00 | Anika Therapeutics to Acquire Parcus Medical and Arthrosurface

2019-12-30 08:22:30 | Anika Therapeutics, Inc. NASDAQ:ANIK Delivered A Weaker ROE Than Its Industry

2019-12-24 08:57:01 | Sarepta SRPT Looks Good: Stock Adds 7.5% in Session

2019-12-20 09:28:02 | Bausch's BHC Arazlo Gets FDA Approval for Acne Vulgaris

2019-12-19 11:35:04 | Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug

2019-12-19 10:18:03 | Biotech Stock Outlook: M&A Activity Retains Growth Streak

2019-12-19 10:02:03 | Epizyme Stock Up on Positive Advisory Votes for Tazemetostat

2019-12-17 10:25:03 | Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis

2019-12-16 15:44:08 | Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern

2019-12-16 09:46:02 | Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote

2019-12-16 08:42:01 | bluebird BLUE Catches Eye: Stock Jumps 6.8%

2019-12-16 08:05:01 | Biogen's Gosuranemab Fails in Phase II Brain Disorder Study

2019-12-13 09:25:02 | Blueprint Medicines BPMC Up More Than 30% YTD: Here's Why

2019-12-12 15:19:08 | ProQR PRQR Begins Dosing in Phase I/II Eye Disorder Study

2019-12-12 14:34:07 | BioCryst Submits NDA for Hereditary Angioedema Candidate

2019-12-12 09:36:02 | Amgen's Osteoporosis Drug Evenity Gets Approval in Europe

2019-12-11 16:11:34 | Is Anika Therapeutics, Inc. ANIK A Good Stock To Buy ?

2019-12-11 14:42:07 | Vertex's Kalydeco Gets EU Approval to Treat CF in Infants

2019-12-11 10:06:03 | VistaGen Up on Fast Track Designation for Anxiety Disorder Drug

2019-12-11 08:40:01 | Intra-Cellular Therapies ITCI in Focus: Stock Moves 6.1% Higher

2019-12-10 09:26:02 | TG Therapeutics' Shares Soar on Positive Early-Stage Data

2019-12-10 08:30:00 | Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques

2019-12-09 16:31:09 | Regeneron Reports Initial Data for Multiple Myeloma Drug